JPMorgan Chase & Co. Has Lowered Expectations for Revvity (NYSE:RVTY) Stock Price

Key Points

• JPMorgan cut its price target on Revvity from $96 to $90 and kept a "neutral" rating, implying about a 9.6% downside from the prior close.
• Multiple brokers have trimmed targets recently, leaving a consensus rating of "Hold" with a consensus target of $106.82 (analyst mix: 4 Buy, 8 Hold, 1 Sell).
• Revvity beat Q1 estimates on EPS and revenue, but issued FY2026 guidance of $5.20–$5.30 EPS and ~$2.8B revenue, below Street views and creating mixed near‑term outlook for the stock.

Revvity (NYSE:RVTY - Get Free Report) had its target price reduced by equities research analysts at JPMorgan Chase & Co. from $96.00 to $90.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage presently has a "neutral" rating on the stock. JPMorgan Chase & Co.'s price target would suggest a potential downside of 9.55% from the company's previous close.

A number of other equities analysts also recently weighed in on the stock. Weiss Ratings downgraded shares of Revvity from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Wednesday, March 18th. Stifel Nicolaus lowered their target price on shares of Revvity from $110.00 to $100.00 and set a "hold" rating for the company in a research note on Wednesday. Barclays reaffirmed an "equal weight" rating and issued a $95.00 price target (down from $118.00) on shares of Revvity in a research note on Tuesday, April 14th. The Goldman Sachs Group decreased their price target on shares of Revvity from $110.00 to $95.00 and set a "neutral" rating for the company in a research note on Tuesday, April 14th. Finally, Wall Street Zen downgraded shares of Revvity from a "buy" rating to a "hold" rating in a research note on Saturday, April 18th. Four analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Revvity has a consensus rating of "Hold" and a consensus target price of $106.82.

Revvity Stock Performance

Shares of RVTY traded up $7.20 during mid-day trading on Wednesday, hitting $99.50. 3,014,194 shares of the company's stock were exchanged, compared to its average volume of 1,293,190. The firm has a market cap of $11.12 billion, a price-to-earnings ratio of 47.84, a price-to-earnings-growth ratio of 1.84 and a beta of 1.05. The stock's 50-day simple moving average is $90.23 and its 200-day simple moving average is $96.82. The company has a quick ratio of 1.40, a current ratio of 1.68 and a debt-to-equity ratio of 0.36. Revvity has a 52 week low of $81.22 and a 52 week high of $118.30.

Revvity (NYSE:RVTY - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $1.06 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.04. The company had revenue of $711.12 million for the quarter, compared to analyst estimates of $704.07 million. Revvity had a net margin of 8.45% and a return on equity of 7.92%. Revvity's revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.01 earnings per share. Revvity has set its FY 2026 guidance at 5.200-5.300 EPS. On average, equities research analysts expect that Revvity will post 5.39 EPS for the current year.

Institutional Investors Weigh In On Revvity

Hedge funds and other institutional investors have recently made changes to their positions in the business. Ascentis Independent Advisors bought a new stake in shares of Revvity during the first quarter worth about $29,000. CYBER HORNET ETFs LLC bought a new stake in shares of Revvity during the second quarter worth about $32,000. Cromwell Holdings LLC increased its position in shares of Revvity by 141.4% during the fourth quarter. Cromwell Holdings LLC now owns 338 shares of the company's stock worth $33,000 after acquiring an additional 198 shares in the last quarter. MUFG Securities EMEA plc purchased a new position in Revvity during the second quarter worth about $34,000. Finally, Headlands Technologies LLC purchased a new position in Revvity during the second quarter worth about $49,000. 86.65% of the stock is owned by institutional investors.

Revvity News Roundup

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Q1 beat — Revvity reported EPS of $1.06 versus consensus $1.02 and revenue of $711.1M vs. $704.1M, showing 7% y/y revenue growth; the beat is the main near-term bullish trigger. Article Title
• Positive Sentiment: Analyst uplift — TD Cowen raised its price target to $120 and kept a Buy rating, signaling further upside potential and likely supporting fresh buying interest. Article Title
• Neutral Sentiment: Underlying performance — company cited ~3% organic growth and portfolio execution that helped offset margin pressure; this context explains the beat but is not unambiguously directional. Article Title
• Neutral Sentiment: Full disclosure available — earnings transcript and slide deck were published (useful for investors to check management commentary on margins, China ImmunoDx plans and product/product-line trends). Article Title
• Negative Sentiment: Guidance trimmed — Revvity set FY26 EPS guidance of $5.20–$5.30 (below Wall Street's ~$5.40) and issued revenue guidance around $2.8B vs. ~ $3.0B consensus, which introduces longer‑term growth/visibility concerns and can limit multiple expansion. Article Title
• Negative Sentiment: Mixed analyst tone — Robert W. Baird cut its price target (to $125) and the broker consensus average sits around "Hold," indicating some analysts are cautious despite the beat. Article Title

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.